Miyoshi A, Kameda H, Nagai S, et al. - This is the first prospective observational study examining the impacts of switching to denosumab (Dmab) from bisphosphonates (BP) or a selective estrogen receptor modulator (SERM) in postmenopausal type 2 diabetes mellitus (T2DM) patients. The sample consisted of T2DM postmenopausal patients whose T‐score of femoral neck or lumbar spine bone mineral density was under −1.0 standard deviation, even after > 6 months of BP or SERM administration. In total, 48 patients were involved in this research, and each group comprised of 12 patients. Findings revealed that switching to Dmab from BP or SERM is helpful in the prevention of osteoporosis progression in postmenopausal patients with T2DM.